RSHF in Colorectal Cancer

Inclusion criteria

• Age > or = 18 years
• Social Insurance
• Performance Index <2
• Life expectancy> 6 months
• adenocarcinoma colorectal (histologically proven)
• Metastases (inoperable or recurrent after surgery),
• hepatic localization and / or lung (up to 3 if one organ metastasis or 3 in total if the two bodies are metastatic). The largest diameter of the metastasis will < ou = 6cm for the liver, < or = 6 cm for the lung. If multiple metastases, the sum of their maximum diameter is 6cm < ou = the liver, < ou = 6 cm for the lung.
• Lesion (s) measurable (s) and evaluable (s)
• CT less than 3 weeks
• Patients must have received at least one prior chemotherapy regimen containing 5FU

• Patients may have received one or more lines of chemotherapy including irinotecan.
• bilirubin <1.5 x ULN
• AST and ALT <5x ULN
• neutrophils> 1.5x109 / L, platelets> 100x109 / L, hemoglobin> 9 g / dL
• TP, TCA Normal (only for patients treated with a permanent implant)
• Informed consent signed.

Exclusion criteria

• contraindication to the administration of irinotecan.
• History of radiotherapy in the thoraco-abdominal-cons indicating further irradiation.
• History of other invasive cancer treated in a period of less than 5 years (basal cell carcinoma and non-invasive cervical excepted)
• Metastatic disease diffuse or more than three metastases in the liver and / or lung during the natural history of disease (excluding any patient is having a complete radiological response on several metastases although 1-3 residual after treatment ( s) medical (at)).
• Location (s) tumor (s) = CTV to less than 12 mm laterally or less than 15 mm in the cranio-caudal, stomach, small intestine, esophagus, trachea, bronchi of right and left pulmonary arteries and right and left.
• Pregnancy or breastfeeding.

• Lack of means or refusal to use effective contraception for men or women of childbearing age.
• Any other concomitant experimental treatment.
• Any other concurrent anticancer therapy, immunotherapy or hormonal therapy.
• Monitoring impossible because of psychological, sociological or because of geographical distance.